Legal & General Group PLC Bei Gene, Ltd. Transaction History

Legal & General Group PLC

  • $470 Billion
  • Q3 2024

A detailed history of Legal & General Group PLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Legal & General Group PLC holds 96,290 shares of BGNE stock, worth $18.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
96,290
Previous 96,290 -0.0%
Holding current value
$18.2 Million
Previous $21.6 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$143.93 - $224.51 $1.07 Million - $1.67 Million
7,430 Added 8.36%
96,290 $21.6 Million
Q2 2024

Aug 14, 2024
BUY
$129.52 - $174.32 $1.59 Million - $2.14 Million
12,297 Added 16.06%
88,860 $12.7 Million
Q1 2024

May 14, 2024
BUY
$141.8 - $181.47 $237,798 - $304,325
1,677 Added 2.24%
76,563 $12 Million
Q4 2023

Feb 15, 2024
SELL
$158.67 - $201.58 $4.73 Million - $6.01 Million
-29,824 Reduced 28.48%
74,886 $13.5 Million
Q3 2023

Nov 14, 2023
BUY
$179.87 - $225.13 $2.1 Million - $2.63 Million
11,687 Added 12.56%
104,710 $18.8 Million
Q2 2023

Aug 14, 2023
BUY
$178.3 - $266.78 $1.78 Million - $2.66 Million
9,982 Added 12.02%
93,023 $16.6 Million
Q1 2023

May 15, 2023
SELL
$215.53 - $274.5 $1.47 Million - $1.87 Million
-6,829 Reduced 7.6%
83,041 $17.9 Million
Q4 2022

Feb 14, 2023
SELL
$125.51 - $229.3 $25.2 Million - $46 Million
-200,752 Reduced 69.08%
89,870 $19.8 Million
Q3 2022

Nov 14, 2022
BUY
$131.8 - $202.24 $785,659 - $1.21 Million
5,961 Added 2.09%
290,622 $39.2 Million
Q2 2022

Aug 22, 2022
BUY
$121.11 - $216.05 $3.38 Million - $6.04 Million
27,945 Added 10.89%
284,661 $46.1 Million
Q1 2022

May 16, 2022
BUY
$146.52 - $269.56 $2.93 Million - $5.4 Million
20,019 Added 8.46%
256,716 $48.4 Million
Q4 2021

Feb 14, 2022
SELL
$248.56 - $389.34 $2.91 Million - $4.56 Million
-11,708 Reduced 4.71%
236,697 $64.1 Million
Q3 2021

Nov 15, 2021
BUY
$249.6 - $403.14 $3.92 Million - $6.33 Million
15,695 Added 6.74%
248,405 $90.2 Million
Q2 2021

Aug 12, 2021
BUY
$292.75 - $367.01 $2.88 Million - $3.62 Million
9,851 Added 4.42%
232,710 $79.9 Million
Q1 2021

May 17, 2021
SELL
$260.64 - $382.12 $691,738 - $1.01 Million
-2,654 Reduced 1.18%
222,859 $77.6 Million
Q4 2020

Feb 12, 2021
SELL
$221.31 - $316.61 $9.53 Million - $13.6 Million
-43,059 Reduced 16.03%
225,513 $58.3 Million
Q3 2020

Nov 13, 2020
BUY
$189.18 - $286.44 $1.94 Million - $2.93 Million
10,241 Added 3.96%
268,572 $76.9 Million
Q2 2020

Aug 14, 2020
BUY
$123.9 - $195.41 $5.79 Million - $9.14 Million
46,759 Added 22.1%
258,331 $48.7 Million
Q1 2020

May 14, 2020
SELL
$121.84 - $173.19 $8.19 Million - $11.6 Million
-67,258 Reduced 24.12%
211,572 $26.1 Million
Q4 2019

Feb 13, 2020
BUY
$115.78 - $208.34 $5 Million - $9.01 Million
43,224 Added 18.35%
278,830 $46.2 Million
Q3 2019

Nov 13, 2019
BUY
$120.61 - $148.29 $4.8 Million - $5.91 Million
39,837 Added 20.35%
235,606 $28.8 Million
Q2 2019

Aug 14, 2019
SELL
$113.99 - $146.86 $2.29 Million - $2.95 Million
-20,105 Reduced 9.31%
195,769 $24.3 Million
Q1 2019

May 15, 2019
BUY
$122.82 - $151.83 $5.16 Million - $6.38 Million
42,053 Added 24.19%
215,874 $28.5 Million
Q4 2018

Feb 15, 2019
BUY
$107.01 - $175.15 $9.24 Million - $15.1 Million
86,355 Added 98.73%
173,821 $24.4 Million
Q3 2018

Nov 20, 2018
BUY
$152.62 - $189.66 $12.6 Million - $15.6 Million
82,466 Added 1649.32%
87,466 $15.1 Million
Q4 2017

Feb 13, 2018
BUY
$79.6 - $114.73 $398,000 - $573,650
5,000
5,000 $489,000

Others Institutions Holding BGNE

# of Institutions
249
Shares Held
45.3M
Call Options Held
292K
Put Options Held
119K
View Full List

About BeiGene, Ltd.

BGNE Quotes by TradingView
  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $19.6B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email